Drug Search Results
More Filters [+]

Trifluoperazine

Alternative Names: trifluoperazine, stelazine
Latest Update: 2022-12-14
Latest Update Note: Clinical Trial Update

Product Description

Trifluoperazine is an inexpensive accessible 'high potency' antipsychotic drug, widely used to treat schizophrenia or related psychoses. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/14974020/)

Mechanisms of Action: D1 Antagonist,D2 Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Bangladesh | Brazil | Canada | Colombia | Cyprus | Dominican Republic | Ecuador | Egypt | Greece | Hong Kong | India | Indonesia | Ireland | Italy | Malaysia | Malta | Mexico | New Zealand | Pakistan | Peru | Russia | Saudi Arabia | Singapore | South Africa | Spain | Sri Lanka | Taiwan | Thailand | Turkey | Ukraine | United Kingdom | United States | Venezuela

Approved Indications: None

Known Adverse Events: None

Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Trifluoperazine

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Recent News Events